Interpace Biosciences, Inc.
IDXG
Get informed when a big investor buys or sells
+ FollowMarket Cap$47.09M
Close$
$-0.82
146.8% downside
Current Fair Value
146.8% downsideOvervalued by 146.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.09 Million |
|---|---|
| Enterprise Value | $46.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $5.55 |
| Beta | 0.61 |
| Outstanding Shares | 22,786,000 |
Return
| Return on Equity | 102.46% |
|---|---|
| Return on Assets | 70.79% |
| Return on Invested Capital | 8.50% |
Valuation & Multiples
| P/E Ratio | 1.64 |
|---|---|
| PEG | -2.91 |
| Price to Sales | 1.75 |
| Price to Book Ratio | 1.75 |
| Enterprise Value to Revenue | 1.27 |
| Enterprise Value to EBIT | 18.45 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-1.43
Average shareholder expectationRevenue Estimate
$9.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$11.10 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Interpace Biosciences, Inc.
111 employees
CEO: Dr. Thomas W. Burnell Ph.D. Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion ...